Clinical Trial

A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1b, partial-blind (Sponsor unblinded), randomized, multicenter, placebo-controlled study. The primary objective of this study is to evaluate the pharmacokinetics (PK) of CSL300 after single and multiple doses in Chinese participants with end stage kidney disease (ESKD) undergoing dialysis.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-08
Trial Details
NCT Number NCT07619820
Lead Sponsor CSL Behring
Conditions End Stage Kidney Disease (ESKD)
Enrollment 24 participants
Start Date 2026-06-17
Primary Completion 2027-08-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-07